金币
UID176556
帖子
主题
积分25160
注册时间2014-6-6
最后登录1970-1-1
听众
性别保密
|
欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
本帖最后由 beiwei5du 于 2016-6-22 23:59 编辑
各位蒲友:
http://www.fda.gov/Drugs/Guidanc ... ces/ucm124785.htm#1
第14个问题中有如下说法:
However, for unstable materials or for materials held longer than the period established in the risk assessment, firms should conduct stability studies according to an approved stability protocol to verify holding periods. The stability studies should include evaluations of the in-process/intermediate materials up to the time of their use in manufacturing a finished drug product and should include long-term monitoring of finished product batches manufactured with the in-process/intermediate materials.
In the latter case, until appropriate stability data are generated, firms should calculate the expiration date assigned to finished product batches based on the date of manufacture/release of the in-process/intermediate material rather than on that of the finished product.
针对于使用“不稳定或实际储存时间超过已建立储存期限的中间体或中间物料”生产的制剂批次,制剂有效期应该按照该中间物料和中间体的生产和放行时间算起,而不是以制剂的生产和放行时间算起??如何理解??
|
|